Jack CR, Bennett DA, Blennow K, Carrillo MC, Feldman HH, Frisoni GB et al. A/T/N: An unbiased descriptive classification scheme for Alzheimer disease biomarkers. Neurology [Internet]. 2016 [cited 2023 May 9];87:539–47. https://n.neurology.org/content/87/5/539.

Mattsson N, Andreasson U, Zetterberg H, Blennow K, Weiner MW, Aisen P et al. Association of Plasma Neurofilament Light With Neurodegeneration in Patients With Alzheimer Disease. JAMA Neurol [Internet]. 2017 [cited 2023 May 9];74:557–66. https://pubmed.ncbi.nlm.nih.gov/28346578/.

Janelidze S, Mattsson N, Palmqvist S, Smith R, Beach TG, Serrano GE et al. Plasma P-tau181 in Alzheimer’s disease: relationship to other biomarkers, differential diagnosis, neuropathology and longitudinal progression to Alzheimer’s dementia. Nat Med [Internet]. 2020 [cited 2023 May 9];26:379–86. https://pubmed.ncbi.nlm.nih.gov/32123385/.

Ashton NJ, Pascoal TA, Karikari TK, Benedet AL, Lantero-Rodriguez J, Brinkmalm G et al. Plasma p-tau231: a new biomarker for incipient Alzheimer’s disease pathology. Acta Neuropathol [Internet]. 2021 [cited 2023 Jun 29];141:709. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8043944/.

Altomare D, Stampacchia S, Ribaldi F, Tomczyk S, Chevalier C, Poulain G et al. Plasma biomarkers for Alzheimer’s disease: a field-test in a memory clinic. J Neurol Neurosurg Psychiatry [Internet]. 2023 [cited 2023 May 9];jnnp-2022-330619. https://pubmed.ncbi.nlm.nih.gov/37012066/.

Donohue MC, Sperling RA, Petersen R, Sun CK, Weiner M, Aisen PS. Association Between Elevated Brain Amyloid and Subsequent Cognitive Decline Among Cognitively Normal Persons. JAMA [Internet]. 2017 [cited 2023 May 9];317:2305–16. https://pubmed.ncbi.nlm.nih.gov/28609533/.

Dickerson BC, Wolk DA. Biomarker-based prediction of progression in MCI: Comparison of AD signature and hippocampal volume with spinal fluid amyloid-β and tau. Front Aging Neurosci [Internet]. 2013 [cited 2023 May 9];5. https://pubmed.ncbi.nlm.nih.gov/24130528/.

Apostolova LG, Dutton RA, Dinov ID, Hayashi KM, Toga AW, Cummings JL et al. Conversion of mild cognitive impairment to Alzheimer disease predicted by hippocampal atrophy maps. Arch Neurol [Internet]. 2006 [cited 2023 May 9];63:693–9. https://pubmed.ncbi.nlm.nih.gov/16682538/.

Bucci M, Chiotis K, Nordberg A. Alzheimer’s disease profiled by fluid and imaging markers: tau PET best predicts cognitive decline. Mol Psychiatry [Internet]. 2021 [cited 2023 May 9];26:5888–98. https://pubmed.ncbi.nlm.nih.gov/34593971/.

Peretti DE, Ribaldi F, Scheffler M, Chicherio C, Frisoni GB, Garibotto V. Prognostic value of imaging-based ATN profiles in a memory clinic cohort. Eur J Nucl Med Mol Imaging [Internet]. 2023 [cited 2023 Jul 4]; https://pubmed.ncbi.nlm.nih.gov/37358619/.

Aschenbrenner AJ, Li Y, Henson RL, Volluz K, Hassenstab J, Verghese P et al. Comparison of plasma and CSF biomarkers in predicting cognitive decline. Ann Clin Transl Neurol [Internet]. 2022 [cited 2023 May 9];9:1739–51. https://pubmed.ncbi.nlm.nih.gov/36183195/.

Cullen NC, Leuzy A, Janelidze S, Palmqvist S, Svenningsson AL, Stomrud E et al. Plasma biomarkers of Alzheimer’s disease improve prediction of cognitive decline in cognitively unimpaired elderly populations. Nat Commun [Internet]. 2021 [cited 2023 May 9];12. https://pubmed.ncbi.nlm.nih.gov/34117234/.

Moscoso A, Grothe MJ, Ashton NJ, Karikari TK, Lantero Rodríguez J, Snellman A et al. Longitudinal Associations of Blood Phosphorylated Tau181 and Neurofilament Light Chain With Neurodegeneration in Alzheimer Disease. JAMA Neurol [Internet]. 2021 [cited 2023 May 9];78:396–406. https://pubmed.ncbi.nlm.nih.gov/33427873/.

Milà-Alomà M, Ashton NJ, Shekari M, Salvadó G, Ortiz-Romero P, Montoliu-Gaya L et al. Plasma p-tau231 and p-tau217 as state markers of amyloid-β pathology in preclinical Alzheimer’s disease. Nat Med [Internet]. 2022 [cited 2023 Jun 29];28:1797–801. https://pubmed.ncbi.nlm.nih.gov/35953717/.

Cullen NC, Leuzy A, Palmqvist S, Janelidze S, Stomrud E, Pesini P et al. Individualized prognosis of cognitive decline and dementia in mild cognitive impairment based on plasma biomarker combinations. Nat Aging [Internet]. 2021 [cited 2023 May 9];1:114–23. https://pubmed.ncbi.nlm.nih.gov/37117993/.

Smirnov DS, Ashton NJ, Blennow K, Zetterberg H, Simrén J, Lantero-Rodriguez J et al. Plasma biomarkers for Alzheimer’s Disease in relation to neuropathology and cognitive change. Acta Neuropathol [Internet]. 2022 [cited 2023 May 9];143:487–503. https://pubmed.ncbi.nlm.nih.gov/35195758/.

Saunders TS, Pozzolo FE, Heslegrave A, King D, McGeachan RI, Spires-Jones MP et al. Predictive blood biomarkers and brain changes associated with age-related cognitive decline. Brain Commun [Internet]. 2023 [cited 2023 May 9];5. https://academic.oup.com/braincomms/advance-article/doi/https://doi.org/10.1093/braincomms/fcad113/7109761.

Ribaldi F, Chicherio C, Altomare D, Martins M, Tomczyk S, Jelescu I et al. Brain connectivity and metacognition in persons with subjective cognitive decline (COSCODE): rationale and study design. Alzheimers Res Ther [Internet]. 2021 [cited 2023 May 9];13. https://pubmed.ncbi.nlm.nih.gov/34034799/.

Albert MS, DeKosky ST, Dickson D, Dubois B, Feldman HH, Fox NC et al. The diagnosis of mild cognitive impairment due to Alzheimer’s disease: Recommendations from the National Institute on Aging-Alzheimer’s Association workgroups on diagnostic guidelines for Alzheimer’s disease. Alzheimer’s & Dementia [Internet]. 2011 [cited 2023 Jun 29];7:270–9. https://onlinelibrary.wiley.com/doi/full/https://doi.org/10.1016/j.jalz.2011.03.008.

Karikari TK, Pascoal TA, Ashton NJ, Janelidze S, Benedet AL, Rodriguez JL et al. Blood phosphorylated tau 181 as a biomarker for Alzheimer’s disease: a diagnostic performance and prediction modelling study using data from four prospective cohorts. Lancet Neurol [Internet]. 2020 [cited 2023 May 9];19:422–33. https://pubmed.ncbi.nlm.nih.gov/32333900/.

Dodich A, Mendes A, Assal F, Chicherio C, Rakotomiaramanana B, Andryszak P et al. The A/T/N model applied through imaging biomarkers in a memory clinic. Eur J Nucl Med Mol Imaging [Internet]. 2020 [cited 2023 May 9];47:247–55. https://pubmed.ncbi.nlm.nih.gov/31792573/.

Klunk WE, Koeppe RA, Price JC, Benzinger TL, Devous MD, Jagust WJ et al. The Centiloid Project: Standardizing quantitative amyloid plaque estimation by PET. Alzheimer’s & Dementia [Internet]. 2015 [cited 2023 Jun 5];11:1–15.e4. https://onlinelibrary.wiley.com/doi/full/https://doi.org/10.1016/j.jalz.2014.07.003.

Mishra S, Gordon BA, Su Y, Christensen J, Friedrichsen K, Jackson K et al. AV-1451 PET imaging of tau pathology in preclinical Alzheimer disease: Defining a summary measure. Neuroimage [Internet]. 2017 [cited 2023 May 9];161:171–8. https://pubmed.ncbi.nlm.nih.gov/28756238/.

Mielke MM, Dage JL, Frank RD, Algeciras-Schimnich A, Knopman DS, Lowe VJ et al. Performance of plasma phosphorylated tau 181 and 217 in the community. Nat Med [Internet]. 2022 [cited 2023 Jun 15];28:1398–405. https://pubmed.ncbi.nlm.nih.gov/35618838/.

Schneider LS, Kennedy RE, Wang G, Cutter GR. Differences in Alzheimer disease clinical trial outcomes based on age of the participants. Neurology [Internet]. 2015 [cited 2023 May 9];84:1121–7. https://pubmed.ncbi.nlm.nih.gov/25681452/.

Boccalini C, Ribaldi F, Hristovska I, Arnone A, Peretti DE, Mu L et al. The impact of tau deposition and hypometabolism on cognitive impairment and longitudinal cognitive decline. Alzheimers Dement [Internet]. 2024 [cited 2024 Mar 12];20:221–33. https://pubmed.ncbi.nlm.nih.gov/37555516/.

Sims JR, Zimmer JA, Evans CD, Lu M, Ardayfio P, Sparks JD et al. Donanemab in Early Symptomatic Alzheimer Disease: The TRAILBLAZER-ALZ 2 Randomized Clinical Trial. JAMA [Internet]. 2023 [cited 2024 Jan 26];330:512–27. https://pubmed.ncbi.nlm.nih.gov/37459141/.

van CH CJS, RJ PA, C B et al. C, M G,. Lecanemab in Early Alzheimer’s Disease. N Engl J Med [Internet]. 2023 [cited 2024 Jan 26];388:142–3. https://pubmed.ncbi.nlm.nih.gov/36449413/.

Aschenbrenner AJ, Gordon BA, Benzinger TLS, Morris JC, Hassenstab JJ. Influence of tau PET, amyloid PET, and hippocampal volume on cognition in Alzheimer disease. Neurology [Internet]. 2018 [cited 2023 May 10];91:e859–66. https://pubmed.ncbi.nlm.nih.gov/30068637/.

Ard MC, Edland SD. Power calculations for clinical trials in Alzheimer’s disease. J Alzheimers Dis [Internet]. 2011 [cited 2023 May 9];26 Suppl 3:369–77. https://pubmed.ncbi.nlm.nih.gov/21971476/.

Marks JD, Syrjanen JA, Graff-Radford J, Petersen RC, Machulda MM, Campbell MR et al. Comparison of plasma neurofilament light and total tau as neurodegeneration markers: associations with cognitive and neuroimaging outcomes. Alzheimers Res Ther [Internet]. 2021 [cited 2023 May 10];13:1–14. https://alzres.biomedcentral.com/articles/https://doi.org/10.1186/s13195-021-00944-y.

Mattsson N, Cullen NC, Andreasson U, Zetterberg H, Blennow K. Association Between Longitudinal Plasma Neurofilament Light and Neurodegeneration in Patients With Alzheimer Disease. JAMA Neurol [Internet]. 2019 [cited 2023 May 10];76:791–9. https://pubmed.ncbi.nlm.nih.gov/31009028/.

Bellaver B, Povala G, Ferreira L, Pedro Ferrari-Souza PC, Leffa J, Lussier DT et al. FZ,. Astrocyte reactivity influences amyloid-β effects on tau pathology in preclinical Alzheimer’s disease. Nat Med [Internet]. 2023 [cited 2023 Jun 21]; https://doi.org/10.1038/s41591-023-02380-x.

Ashton NJ, Janelidze S, Al Khleifat A, van der Leuzy A, Karikari TK et al. A multicentre validation study of the diagnostic value of plasma neurofilament light. Nat Commun [Internet]. 2021 [cited 2023 Jun 29];12. https://pubmed.ncbi.nlm.nih.gov/34099648/.

Zhu N, Santos-Santos M, Illán-Gala I, Montal V, Estellés T, Barroeta I et al. Plasma glial fibrillary acidic protein and neurofilament light chain for the diagnostic and prognostic evaluation of frontotemporal dementia. Transl Neurodegener [Internet]. 2021 [cited 2023 May 10];10. https://pubmed.ncbi.nlm.nih.gov/34893073/.

Pichet Binette A, Palmqvist S, Bali D, Farrar G, Buckley CJ, Wolk DA et al. Combining plasma phospho-tau and accessible measures to evaluate progression to Alzheimer’s dementia in mild cognitive impairment patients. Alzheimers Res Ther [Internet]. 2022 [cited 2023 May 10];14. https://pubmed.ncbi.nlm.nih.gov/35351181/.

Palmqvist S, Janelidze S, Stomrud E, Zetterberg H, Karl J, Zink K et al. Performance of Fully Automated Plasma Assays as Screening Tests for Alzheimer Disease-Related β-Amyloid Status. JAMA Neurol [Internet]. 2019 [cited 2023 May 10];76:1060–9. https://pubmed.ncbi.nlm.nih.gov/31233127/.

Ashton NJ, Janelidze S, Mattsson-Carlgren N, Binette AP, Strandberg O, Brum WS et al. Differential roles of Aβ42/40, p-tau231 and p-tau217 for Alzheimer’s trial selection and disease monitoring. Nature Medicine 2022 28:12 [Internet]. 2022 [cited 2023 Jul 26];28:2555–62. https://www.nature.com/articles/s41591-022-02074-w.

Mendes AJ, Ribaldi F, Lathuiliere A, Ashton NJ, Janelidze S, Zetterberg H et al. Head-to-head study of diagnostic accuracy of plasma and cerebrospinal fluid p-tau217 versus p-tau181 and p-tau231 in a memory clinic cohort. J Neurol [Internet]. 2024 [cited 2024 Jan 26]; https://pubmed.ncbi.nlm.nih.gov/38195896/.

Angioni D, Hansson O, Bateman RJ, Rabe C, Toloue M, Braunstein JB et al. Can We Use Blood Biomarkers as Entry Criteria and for Monitoring Drug Treatment Effects in Clinical Trials? A Report from the EU/US CTAD Task Force. J Prev Alzheimers Dis [Internet]. 2023 [cited 2023 Jun 21]; https://link.springer.com/article/https://doi.org/10.14283/jpad.2023.68.

Mayblyum DV, Becker JA, Jacobs HIL, Buckley RF, Schultz AP, Sepulcre J et al. Comparing PET and MRI Biomarkers Predicting Cognitive Decline in Preclinical Alzheimer Disease. Neurology [Internet]. 2021 [cited 2023 May 10];96:E2933–43. https://pubmed.ncbi.nlm.nih.gov/33952655/.

Mattsson-Carlgren N, Salvadó G, Ashton NJ, Tideman P, Stomrud E, Zetterberg H et al. Prediction of Longitudinal Cognitive Decline in Preclinical Alzheimer Disease Using Plasma Biomarkers. JAMA Neurol [Internet]. 2023 [cited 2023 May 9];80. https://pubmed.ncbi.nlm.nih.gov/36745413/.

Donohue MC, Sperling RA, Salmon DP, Rentz DM, Raman R, Thomas RG et al. The Preclinical Alzheimer Cognitive Composite: Measuring Amyloid-Related Decline. JAMA Neurol [Internet]. 2014 [cited 2024 Mar 13];71:961. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4439182/.

Ashton NJ, Puig-Pijoan A, Milà-Alomà M, Fernández-Lebrero A, García-Escobar G, González-Ortiz F et al. Plasma and CSF biomarkers in a memory clinic: Head-to-head comparison of phosphorylated tau immunoassays. Alzheimers Dement [Internet]. 2023 [cited 2023 Jun 29];19. https://pubmed.ncbi.nlm.nih.gov/36370462/.